Phio Pharmaceuticals Corp. (PHIO) Stock

Phio Pharmaceuticals Corp., headquartered in Marlborough, Massachusetts, specializes in the development of immuno-oncology therapeutics in the United States. Founded in 2011 and previously known as RXi Pharmaceuticals Corporation, the company rebranded to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals leverages its innovative INTASYL therapeutic platform, which targets both tumor and immune cells by modulating genes within the immune system.

At the core of Phio Pharmaceuticals' pipeline are several promising candidates. PH-762 activates immune cells to effectively recognize and eliminate cancer cells by reducing the expression of the checkpoint protein PD-1, enhancing the efficacy of adoptive cell transfer (ACT) immunotherapy. PH-894 targets the epigenetic protein BRD4, a crucial regulator of gene expression, for use in ACT, aiming to silence its activity to combat cancer. Additionally, PH-804 focuses on targeting the suppressive immune receptor TIGIT, found on T cells and natural killer cells, to further enhance ACT therapies.

In collaboration with AgonOx Inc., Phio Pharmaceuticals is advancing the clinical development of novel T cell-based cancer immunotherapies. These partnerships underscore Phio Pharmaceuticals' commitment to expanding treatment options and improving outcomes for patients battling cancer through cutting-edge immunotherapy approaches. With a dedication to scientific excellence and transformative research, the company continues to push boundaries in the field of immuno-oncology.